Prosecution Insights
Last updated: November 22, 2026
Application No. 18/183,476

INTRAVENOUS SET WITH PUMP INTERFACE FOR RAPID INFUSION VIA REUSABLE DRIVER

Final Rejection §103
Filed
Mar 14, 2023
Examiner
NG, HENRY
Art Unit
3741
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cardinal Health Inc.
OA Round
4 (Final)
63%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
153 granted / 243 resolved
-7.0% vs TC avg
Strong +52% interview lift
Without
With
+51.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
24 currently pending
Career history
267
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
53.1%
+13.1% vs TC avg
§102
22.7%
-17.3% vs TC avg
§112
19.9%
-20.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 243 resolved cases

Office Action

§103
FINAL ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is the fourth office action on the merits. This office action is in response to the amendment filed on 10/14/2026. Applicant has amended claims 1, 10, and 15-16. Claims 5, 10-13, 15, and 20 remain withdrawn from further consideration. Claims 1-4, 6-9, 16-17, and 19 are pending and examined. Claim Objections Claims 1, 16-17, and 19 are objected to because of the following informalities: Claim 1, line 13: “driver interface” is believed to be in error for --drive interface-- (see claim 1, line 9) Claim 16, line 14: “driver interface” is believed to be in error for --drive interface-- (see claim 1, line 6) Claim 17, line 2: “the separate handheld external driver” is believed to be in error for --the removable external driver-- (see claim 16, line 6) Claim 19, lines 2 and 4-5: “the separate handheld external driver” (two instances) is believed to be in error for --the removable external driver-- (see claim 16, line 6) Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1 and 6-8 are rejected under 35 U.S.C. 103 as being unpatentable over Vanderveen (US 4,608,042: IDS reference), in view of Honstein (US 5,456,388). Regarding claim 1, Vanderveen teaches (Fig. 3) an intravenous (IV) infusion set, comprising: an infusion component (72); a first IV tube coupled to a first inlet port (see annotated Fig. 3 on next page) of the infusion component (72); a second IV tube coupled to an outlet port (see annotated Fig. 3 on next page) of the infusion component (72); and a syringe interface (see annotated Fig. 3 on next page) coupled to a second inlet port (74) of the infusion component (72), the syringe interface comprising: a housing (see annotated Fig. 3 below) configured to receive a syringe (18); an outlet port (see annotated Fig. 3 below) coupled to (via needle 84) the second inlet port (74) of the infusion component (72); and a plunger (80). PNG media_image1.png 799 392 media_image1.png Greyscale However, Vanderveen does not teach the specifics of the syringe interface comprising: a drive interface coupling configured to receive a drive interface, wherein the drive interface is configured to be rotated by a driver to slidably move the plunger within a body of the syringe to dispense a fluid from the syringe, wherein the driver is a separate removable device disposed externally to the syringe interface and removable from the driver interface when the syringe interface is disposed on the second inlet port of the infusion component. Honstein teaches (Figs. 1, 3, and 5) a syringe interface comprising: a housing (110 – Fig. 1) configured to receive a syringe (20 – Fig. 1); an outlet port (29 – Fig. 3); and a drive interface coupling (45) configured to receive a drive interface (50 – Figs. 1 and 5), wherein the drive interface (50) is configured to be rotated by a driver (54) to slidably move a plunger (25 – Fig. 1) within a body (21 – Figs. 1 and 5) of the syringe (20) to dispense a fluid (24) from the syringe (20) – (see col. 7, ll. 5-8 for a description of how the drive member 54 rotates the drive interface 50 to move plunger 25), wherein the driver (54) is a separate removable device (Fig. 5 shows the driver 54 as a separate removable device) disposed externally to the syringe interface (as shown in Fig. 1, driver 54 is outside of the syringe interface components, which include syringe 20, drive interface coupling 45, and drive interface 50) and removable from the driver interface (50) – (Fig. 5 shows driver 54 as being removable from driver interface 50). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to replace Vanderveen’s syringe interface with Honstein’s syringe interface, because it has been held that a simple substitution of one known element (Honstein’s syringe interface as shown in Honstein, Fig. 1) for another (Vanderveen’s syringe interface as shown in Vanderveen, Fig. 3) to obtain predictable results (in this case, to provide an improved handheld injection device for metering small amounts of fluid material, as taught by Honstein, col. 3, ll. 57-59) was an obvious extension of prior art teachings, KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007), MPEP 2143 (I)(B), therefore providing: the driver (Honstein, 54) is removable from the driver interface (Honstein, 50) when the syringe interface (Honstein, 20) is disposed on the second inlet port (Vanderveen, 74) of the infusion component (Vanderveen, 72). Regarding claim 6, Vanderveen, in view of Honstein, teaches the invention as claimed and as discussed above for claim 1, and the combination further teaches the drive interface (Honstein, 50) is provided as a removable component separated from the rest of the IV infusion set (Vanderveen, Fig. 3) – (Honstein’s Fig. 5 shows drive interface 50 as a removably separate element. When combined with Vanderveen’s IV infusion set, Honstein’s drive interface 50 would also be a removably separate element). Regarding claim 7, Vanderveen, in view of Honstein, teaches the invention as claimed and as discussed above for claim 1, and the combination further teaches (Honstein, Figs. 1 and 5) the drive interface (50) is a removable component pre-coupled to the syringe interface (comprising syringe 20 and drive interface coupling 45) – (Fig. 5 shows drive interface 50 as a removably separate element; Fig. 1 shows drive interface 50 pre-coupled to the syringe interface). Regarding claim 8, Vanderveen, in view of Honstein, teaches the invention as claimed and as discussed above for claim 1, and the combination further teaches (Honstein, Figs. 1 and 3) the outlet port (29) of the syringe interface (comprising syringe 20 and drive interface coupling 45) is configured to receive an outlet port (left most end of barrel 22) of the syringe (20) – (as shown in Figs. 1 and 3). Claim 9 is rejected under 35 U.S.C. 103 as being unpatentable over Vanderveen (US 4,608,042: IDS reference), in view of Honstein (US 5,456,388), and in further view of Chelak (US 2019/0275312 A1). Regarding claim 9, Vanderveen, in view of Honstein, teaches the invention as claimed and as discussed above for claim 1, and Vanderveen further teaches (Fig. 1) the at least one infusion component (70 would be another infusion component) comprises: a fluid connector (16) configured to be coupled to a fluid container (14). However, Vanderveen, in view of Honstein, does not teach a luer lock connector configured to be coupled to a catheter inserted into a patient. Chelak teaches a similar IV infusion set (Fig. 2) comprising at least one infusion component (180) and a syringe interface (connects to 180 – see ¶ [0077], ll. 14-16), and further teaches: a luer lock connector (164) configured to be coupled (via stabilization body 120) to a catheter (210) inserted into a patient (¶ [0068], ll. 1-3). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to modify Vanderveen, in view of Honstein, by including a luer lock connector configured to be coupled to a catheter inserted into a patient, in order to lock the catheter in place, as taught by Chelak (¶ [0068], ll. 5-8). Claims 16-17 are rejected under 35 U.S.C. 103 as being unpatentable over Vanderveen (US 4,608,042: IDS reference), in view of Chelak (US 2019/0275312 A1) and Honstein (US 5,456,388). Regarding claim 16, Vanderveen teaches (Fig. 1) a method of using an intravenous (IV) set assembly, the method comprising: coupling a first end (top end of 16) of an IV set (the IV set shown in Fig. 1) to a fluid container (14); coupling a second end of the IV set to a patient (where it says “TO PATIENT”); flowing fluid from the fluid container (14) to the patient (col. 6, ll. 49-50: “infusion of fluids to the patient from fluid source 14”); and a syringe interface (see annotated Fig. 1 below) of the IV set; placing a syringe (18) containing fluid (col. 3, l. 53: “fluid filled syringe 18”) within a housing (see annotated Fig. 1 below) of the syringe interface; and a plunger (80 – shown in Fig. 3). PNG media_image2.png 539 450 media_image2.png Greyscale However, Vanderveen does not teach coupling the second end of the IV set to a catheter inserted into the patient. Chelak teaches a similar IV set (Fig. 2) comprising at least one infusion component (180) and a syringe interface (connects to 180 – see ¶ [0077], ll. 14-16), and further teaches: coupling a second end (164) of the IV set to a catheter (210) inserted into a patient (¶ [0068], ll. 1-3). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to modify Vanderveen by including a catheter, in order to provide regular administration of fluids or medications into the patient, as taught by Chelak (¶ [0004], ll. 1-4), therefore providing: coupling the second end (Vanderveen, Fig. 1 where it says “TO PATIENT”) of the IV set to a catheter (Chelak, 210) inserted into the patient. However, Vanderveen, in view of Chelak, does not teach coupling a removable external driver to a drive interface of the syringe interface of the IV set; operating the removable external driver externally to the housing to rotate the drive interface of the syringe interface to slidably move the plunger within a body of the syringe; dispensing the fluid from the syringe to the patient at a fluid flow rate based on the rotation of the drive interface of the syringe interface; and removing the removable external driver from the driver interface. Honstein teaches (Figs. 1, 3, and 5) placing a syringe (20 – Fig. 1) containing fluid (24) within a housing (110 – Fig. 1) of a syringe interface (comprising, 20, 45, 50, and 110), and further teaches: coupling a removable external driver (54 – Fig. 5 shows the driver 54 as a separate removable device) to a drive interface (50 – Figs. 1 and 5) of the syringe interface; operating the removable external driver (54) externally to the housing (110) – (as shown in Fig. 1, driver 54 is outside of housing 110) to rotate the drive interface (50) of the syringe interface to slidably move a plunger (25 – Fig. 1) within a body (21 – Figs. 1 and 5) of the syringe (20) – (see col. 7, ll. 5-8 for a description of how the drive member 54 rotates the drive interface 50 to move plunger 25); and dispensing the fluid (24) from the syringe (20) to a patient at a fluid flow rate based on the rotation of the drive interface (50) of the syringe interface (col. 7, ll. 8-12: “Since piston 25 exerts hydrostatic pressure on adhesive 24 in bore 23 of barrel 22, this action causes precisely controllable amounts of adhesive to be expelled through bore 58 of small diameter outlet tube 29 located at the front of barrel 22”); and removing the removable external driver (54) from the driver interface (50) – (Fig. 5 shows the driver 54 being removed from the driver interface 50). It would have been obvious to a person having ordinary skill in the art before the effective filing date of the claimed invention to replace Vanderveen’s syringe interface with Honstein’s syringe interface, because it has been held that a simple substitution of one known element (Honstein’s syringe interface as shown in Honstein, Fig. 1) for another (Vanderveen’s syringe interface as shown in Vanderveen, Fig. 3) to obtain predictable results (in this case, to provide an improved handheld injection device for metering small amounts of fluid material, as taught by Honstein, col. 3, ll. 57-59) was an obvious extension of prior art teachings, KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 415-421, 82 USPQ2d 1385, 1395-97 (2007), MPEP 2143 (I)(B), therefore providing the above method steps as outlined in Honstein. Regarding claim 17, Vanderveen, in view of Chelak and Honstein, teaches the invention as claimed and as discussed above for claim 16, and the combination further teaches (Honstein, Fig. 1) operating the separate handheld external driver (54) to rotate the drive interface (50) of the syringe interface (comprising, 20, 45, 50, and 110) at one of a fixed speed and a variable speed (col. 7, ll. 5-12: “lead screw 50 and piston 25 may be advanced longitudinally with respect to insert 45 and barrel 22 of dispenser 20 by rotating thumbwheel 54 with respect to the barrel. Since piston 25 exerts hydrostatic pressure on adhesive 24 in bore 23 of barrel 22, this action causes precisely controllable amounts of adhesive to be expelled through bore 58 of small diameter outlet tube 29 located at the front of barrel 22”). Allowable Subject Matter Claims 2-4 and 19 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims, and rewritten to overcome the claim objections listed above. REASONS FOR ALLOWANCE The following is an examiner’s statement of reasons for allowance: The closest prior art of record, Honstein (US 5,456,388), does not teach a drive shaft of the driver. As shown in Figs 4-6 of Honstein, the driver 54 is merely a thumbwheel which couples to the drive interface 50 of the syringe interface. The thumbwheel 54 does not comprise a drive shaft. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Response to Arguments Applicant’s arguments regarding the new limitations in claims 1 and 16 have been considered but are moot in view of the new ground(s) of rejection, necessitated by Applicant's amendments. To the extent possible, Applicant's arguments have been addressed in the body of the prior-art rejections at the appropriate locations. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HENRY NG whose telephone number is (571)272-2318. The examiner can normally be reached M-F 9:30 AM - 6:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Devon Kramer can be reached at 571-272-7118. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HENRY NG/ /GERALD L SUNG/ Primary Examiner, Art Unit 3741 Examiner, Art Unit 3741
Read full office action

Prosecution Timeline

Show 1 earlier event
Dec 19, 2025
Non-Final Rejection mailed — §103
Feb 25, 2026
Response Filed
Apr 01, 2026
Final Rejection mailed — §103
May 27, 2026
Request for Continued Examination
Jun 03, 2026
Response after Non-Final Action
Jul 16, 2026
Non-Final Rejection mailed — §103
Oct 14, 2026
Response Filed
Nov 05, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799899
GAS TURBINE ENGINE
1y 3m to grant Granted Nov 17, 2026
Patent 12779137
MINIATURE IV INFUSION LINE AIR ELIMINATOR
3y 6m to grant Granted Nov 03, 2026
Patent 12781966
GAS TURBINE ENGINE CONFIGURED FOR DECREASED DIFFUSER WINDAGE AND METHOD OF ASSEMBLING THE SAME
2y 6m to grant Granted Nov 03, 2026
Patent 12781662
HYBRID GAS TURBINE ENGINE
1y 2m to grant Granted Nov 03, 2026
Patent 12760684
AIRCRAFT TURBINE ENGINE ASSEMBLY COMPRISING A HOLDER FOR FITTINGS
3y 4m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
63%
Grant Probability
99%
With Interview (+51.9%)
2y 9m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 243 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month